Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmaCyte Biotech, Inc. (formerly Nuvilex, Inc.) on January 9, 2015, covering events occurring on January 6, 2015. The filing documents a corporate name change and ticker symbol update executed via a short-form merger under Nevada Revised Statutes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate structure and does not contain financial performance data.
Material Changes
- Corporate Name: Changed from "Nuvilex, Inc." to "PharmaCyte Biotech, Inc." effective January 6, 2015.
- Ticker Symbol: Changed from "NVLX" to "PMCB."
- Legal Structure: A wholly-owned subsidiary was merged with and into the Company, with the Company as the surviving entity.
- Impact on Stakeholders: The merger and name change do not affect the rights of security holders, creditors, customers, or suppliers.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No risks or contingencies were disclosed in this specific report. The Company issued press releases on January 7 and January 8, 2015, to announce the name change and new ticker symbol, respectively.
Investor Verification Checklist
- Verify the new ticker symbol "PMCB" on trading platforms.
- Confirm the legal name change to "PharmaCyte Biotech, Inc." in corporate registries.
- Review the attached Articles of Merger (Exhibit 3.1) for details on the short-form merger.
- Check subsequent filings for financial data, as this 8-K contains no financial statements.